Dr Lynne Porter Alexander, MD | |
621 Carolina Ave, Bogalusa, LA 70427-3318 | |
(985) 732-2524 | |
Not Available |
Full Name | Dr Lynne Porter Alexander |
---|---|
Gender | Female |
Speciality | Dermatology |
Location | 621 Carolina Ave, Bogalusa, Louisiana |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205055977 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | 010679 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Lynne Porter Alexander, MD 621 Carolina Ave, Bogalusa, LA 70427-3318 Ph: (985) 732-2524 | Dr Lynne Porter Alexander, MD 621 Carolina Ave, Bogalusa, LA 70427-3318 Ph: (985) 732-2524 |
News Archive
Symmetry Medical Inc., a leading independent provider of products to the global orthopaedic device industry and other medical markets, announced today a restructuring that includes a facility consolidation and other staff reductions designed to increase operational efficiency and drive annualized cost savings.
Medicalis today announced the commercialization of its next generation Radiology Collaborative Workflow Solutions™ offering providers a sophisticated technology platform to enhance productivity and ensure the delivery of measureable high-quality radiology care. For the first time, the company will showcase its three groundbreaking Collaborative Workflow Solutions at the 96th annual meeting of the Radiological Society of North America (RSNA), Nov. 28 – Dec. 2, in Chicago (Booth 4050).
Health care consultant group Accretive plans to answer questions from the Minnesota senator and respond to the state's attorney general in a report to be released today.
Nanotherapeutics, Inc., today announced that it has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major).
› Verified 1 days ago